IPO registrations (S-1, F-1) · Registrants

Merus N.V.

SEC CIK
1651311 · filings on EDGAR ↗
Former names
Merus B.V. (2015–2016)
Registration
Form F-1, first filed 2015-10-19, last 2019-04-03; 2 initial registrations, 4 amendments
Outcome
Final prospectus filed 2016-05-20; declared effective 2016-05-18
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
P7
Business address
YALELAAN 62, 3584 Cm Utrecht, DE
EDGAR entity type
operating
Insiders and CEO pay
Merus N.V. on the corporate pages

Offering terms

Proposed price range
$14.00–$16.00 per share (F-1/A filed 2016-05-09)
Final price
$10.00 per share, below the range (424B4 filed 2016-05-20, an initial public offering)
Shares sold
5,500,000
Gross proceeds
$55,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol MRUS
Lead underwriters
Citigroup
Syndicate
Jefferies; Guggenheim Securities; Wedbush Securities

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 14

FiledFormWhat it isName as filedEDGAR
2015-10-19F-1F-1 (foreign registration)Merus B.V.0001193125-15-346981 ↗
2016-01-21F-1/AF-1/A (amendment)Merus B.V.0001193125-16-434605 ↗
2016-04-08F-1/AF-1/A (amendment)Merus B.V.0001193125-16-535709 ↗
2016-05-09F-1/AF-1/A (amendment)Merus B.V.0001193125-16-582683 ↗
2016-05-18EFFECTEFFECT (declared effective)Merus B.V.9999999995-16-004704 ↗
2016-05-20424B4424B4 (final prospectus)Merus N.V.0001193125-16-597603 ↗
2017-06-16EFFECTEFFECT (declared effective)Merus N.V.9999999995-17-001570 ↗
2018-12-27F-1F-1 (foreign registration)Merus N.V.0001193125-18-359219 ↗
2019-04-03F-1/AF-1/A (amendment)Merus N.V.0001193125-19-096714 ↗
2019-04-05EFFECTEFFECT (declared effective)Merus N.V.9999999995-19-000618 ↗
2019-08-27EFFECTEFFECT (declared effective)Merus N.V.9999999995-19-001976 ↗
2019-08-29EFFECTEFFECT (declared effective)Merus N.V.9999999995-19-002012 ↗
2020-05-05EFFECTEFFECT (declared effective)Merus N.V.9999999995-20-001033 ↗
2020-05-05EFFECTEFFECT (declared effective)Merus N.V.9999999995-20-001034 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2016-05-09F-1/Aregistration statement$14.00–$16.00$15.004,333,333$64,999,995Nasdaq MRUS4primary document; range, price sentence, shares headline, proceeds computed, cover names 4document ↗
2016-05-20424B4final prospectus$10.005,500,000$55,000,000Nasdaq MRUS4primary document; price sentence, shares headline, proceeds table, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
INCYTE CORPTenPercentOwner32017–2021
Bakker LexOfficerSVP, Chief Development Officer202020–2022
de Koning JohnDirector12020
de Kruif JohnOfficerChief Technology Officer; SVP & Chief Technology Officer202020–2022
Greig RussellDirector12020
Iwicki Mark TDirector92020–2025
Kanavy LenDirector82020–2025
Liu HuiOfficerEVP, CBO & Head of Merus US212020–2024
Lundberg Sven AnteDirector,OfficerPresident, CEO & PEO; President, CEO & PFO212020–2025
Mehra AnandDirector82020–2025
PERRY GREGORY DDirector; OfficerChief Financial Officer; Chief Financial Officer & PFO92020–2025
Sandor VictorDirector82020–2025
Shuman HarryOfficerChief Accounting Officer; VP Controller, PAO262020–2025
Silverman Peter B.OfficerCOO & GC; EVP, GC and Head of Utrecht; EVP & General Counsel172020–2025
Sirulnik AndresOfficerEVP & Chief Medical Officer22020
Throsby MarkOfficerEVP & Chief Scientific Officer152020
BIOTECHNOLOGY VALUE FUND II LPOther152020–2021
BIOTECHNOLOGY VALUE FUND L POther; TenPercentOwner152020–2021
Biotechnology Value Trading Fund OS LPOther152020–2021
BVF INC/ILTenPercentOwner152020–2021
BVF PARTNERS L P/ILTenPercentOwner152020–2021
BVF Partners OS Ltd.Other152020–2021
LAMPERT MARK NTenPercentOwner152020–2021
BVF GP HOLDINGS LLCOther; TenPercentOwner132020–2021
BVF I GP LLCOther; TenPercentOwner132020–2021
BVF II GP LLCOther132020–2021
Pucci PaoloDirector82020–2025
Joe AndrewOfficerSVP, CMO62020–2024
Geuijen Cecile A WOfficerSVP & Chief Scientific Officer32021–2022
GOWEN MAXINEDirector82021–2025
Haddock JasonDirector42024–2025
Zohren FabianOfficerChief Medical Officer42024–2025
GENMAB A/STenPercentOwner52025

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2019-01-02Merus N.V.Biotechnology$15,000,000$15,000,00011
2018-02-28Merus N.V.Biotechnology$55,799,946$55,799,94691
2017-01-24Merus N.V.Biotechnology$80,000,000$80,000,00011

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Form D issuerMerus N.V.Form D private offeringsCIK (EXACT)
SEC filerMerus N.V.SEC filers (EDGAR)CIK (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, DE first:

More with this interest.

In other datasets, the same topic (Health) in DE:

Interests: Pharmaceutical Preparations · Health